Author’s response to reviews

Title: MONITORING THE RESPONSIVENESS OF T AND ANTIGEN PRESENTING CELL COMPARTMENTS IN BREAST CANCER PATIENTS IS USEFUL TO PREDICT CLINICAL TUMOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY

Authors:
David Bernal-Estévez (dabernale@unal.edu.co)
Oscar García (osaga72@hotmail.com)
Ramiro Sánchez (ramirosr@cable.net.co)
Carlos Parra-Lopez (caparral@unal.edu.co)

Version: 2 Date: 24 Nov 2017

Author’s response to reviews:

Dear BMC Cancer Editor

We would like to thank you for the final steps of this process. We have addressed all the minor changes required by the Editor and the reviewer. We consider that with these suggestions it as an improved and final version of the manuscript.

Please find below, for your perusal, point by point our response to all the inquiries of the reviewers.

Kind Regards,

_____________________
Carlos A. Parra-López

Editor Comments:

Please perform the following revisions to your manuscript:

1. Please add a 'Conclusion' section after the discussion.

In line 391 we add a “conclusion” section
2. On uploading your revisions, please remove all tracking/highlighting and instead upload a single clean version of the manuscript.

We have removed the tracking option from the manuscript document.

3. Under 'Ethical approval and consent to participate' (within declarations) please add your ethical approval reference number.

In line 401 we add the ethical approval number “ACT-018”

4. Under Funding (within declarations) - please add the phrase: 'The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript'.

From line 414 to 416 we add the recommended phrase.

5. Please improve the resolution of your figures.

We revise all figures and increase the final resolution (1200 DPI) and adjusted the size.

Reviewer reports:

Sylvain Ladoire (Reviewer 1): The authors clearly answer to the comments in their point by point reply letter, and all the requested corrections have been made.

Minor points:

Table 1:

SBR grade distribution should be added

We add the SBR grade in the Table 1

Please remove "basal-like" (transcriptomic definition) and use "triple negative" in stead of

We change the term “basal-like” to “triple negative”

Please clarify your definition of breast cancer subtype and HER2 positivity, as only 1 HER2 overexpressing BC appear since 5 HER2 positivity

We have added a commentary to the table clarifying the criteria of Her2/neu overexressed patients, only 1 fulfill the criteria (ER- Her2/neu+), the other 4 patients ex-press Her2/neu but also ER or PR.

The authors’ response letter has been included as a supplementary file